| Dr Michael Sydenham Clarke, MD | |
|
250 Hospital Pl, Soldotna, AK 99669-6999 | |
| (907) 714-4529 | |
| Not Available |
| Full Name | Dr Michael Sydenham Clarke |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 14 Years |
| Location | 250 Hospital Pl, Soldotna, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114248879 | NPI | - | NPPES |
| E-11363 | Other | AR | AR MEDICAL LICENSE |
| A145061 | Other | CA | CA MEDICAL LICENSE |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Arkansas Regional Medical Center | Harrison, AR | Hospital |
| Entity Name | North Arkansas Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962741801 PECOS PAC ID: 5193615896 Enrollment ID: O20040317000487 |
News Archive
Anti-smoking television advertisements that appeal to viewers' emotions are more persuasive when they use anger rather than sadness, a Dartmouth-Cornell study suggests.
President Obama's appeal to members of Congress to not walk away from health care reform and the millions of Americans who are counting on it provides hope to the many heart disease and stroke patients who are struggling to get the care they need or are one step away from medical bankruptcy.
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues in the second quarter of 2010 increased 36 percent versus revenues in the second quarter of 2009.
Millennium: The Takeda Oncology Company today announced data examining the use of VELCADE in the treatment of patients with relapsed or refractory light chain (AL) amyloidosis. Amyloidosis is a rare condition in which excessive proteins build up in organs or tissues, such as the heart, kidney or liver. These data were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois, June 4-8, 2010.
The human body is proficient at making collagen. And human laboratories are getting better at it all the time. In a development that could lead to better drug design and new treatments for disease, Rice University researchers have made a major step toward synthesizing custom collagen. Rice scientists who have learned how to make collagen - the fibrous protein that binds cells together into organs and tissues - are now digging into its molecular structure to see how it forms and interacts with biological systems.
› Verified 6 days ago
| Entity Name | Michael S. Clarke, M.d., P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376029041 PECOS PAC ID: 7214287259 Enrollment ID: O20180912001788 |
News Archive
Anti-smoking television advertisements that appeal to viewers' emotions are more persuasive when they use anger rather than sadness, a Dartmouth-Cornell study suggests.
President Obama's appeal to members of Congress to not walk away from health care reform and the millions of Americans who are counting on it provides hope to the many heart disease and stroke patients who are struggling to get the care they need or are one step away from medical bankruptcy.
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues in the second quarter of 2010 increased 36 percent versus revenues in the second quarter of 2009.
Millennium: The Takeda Oncology Company today announced data examining the use of VELCADE in the treatment of patients with relapsed or refractory light chain (AL) amyloidosis. Amyloidosis is a rare condition in which excessive proteins build up in organs or tissues, such as the heart, kidney or liver. These data were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois, June 4-8, 2010.
The human body is proficient at making collagen. And human laboratories are getting better at it all the time. In a development that could lead to better drug design and new treatments for disease, Rice University researchers have made a major step toward synthesizing custom collagen. Rice scientists who have learned how to make collagen - the fibrous protein that binds cells together into organs and tissues - are now digging into its molecular structure to see how it forms and interacts with biological systems.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Sydenham Clarke, MD 250 Hospital Pl, Soldotna, AK 99669-6999 Ph: (907) 714-4529 | Dr Michael Sydenham Clarke, MD 250 Hospital Pl, Soldotna, AK 99669-6999 Ph: (907) 714-4529 |
News Archive
Anti-smoking television advertisements that appeal to viewers' emotions are more persuasive when they use anger rather than sadness, a Dartmouth-Cornell study suggests.
President Obama's appeal to members of Congress to not walk away from health care reform and the millions of Americans who are counting on it provides hope to the many heart disease and stroke patients who are struggling to get the care they need or are one step away from medical bankruptcy.
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues in the second quarter of 2010 increased 36 percent versus revenues in the second quarter of 2009.
Millennium: The Takeda Oncology Company today announced data examining the use of VELCADE in the treatment of patients with relapsed or refractory light chain (AL) amyloidosis. Amyloidosis is a rare condition in which excessive proteins build up in organs or tissues, such as the heart, kidney or liver. These data were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois, June 4-8, 2010.
The human body is proficient at making collagen. And human laboratories are getting better at it all the time. In a development that could lead to better drug design and new treatments for disease, Rice University researchers have made a major step toward synthesizing custom collagen. Rice scientists who have learned how to make collagen - the fibrous protein that binds cells together into organs and tissues - are now digging into its molecular structure to see how it forms and interacts with biological systems.
› Verified 6 days ago
Nicole Marie Nilson, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 250 Hospital Pl, Soldotna, AK 99669 Phone: 907-714-5831 | |
Leon S Mensch, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 250 Hospital Pl, Soldotna, AK 99669 Phone: 907-714-4502 | |
Curtis L Buchholz, Pathology Medicare: Not Enrolled in Medicare Practice Location: 44455 Sterling Hwy, Soldotna, AK 99669 Phone: 907-262-3557 Fax: 907-262-6505 | |
Talat Mehmood Nazir, MD, DO Pathology Medicare: Not Enrolled in Medicare Practice Location: 44455 Sterling Hwy, Soldotna, AK 99669 Phone: 907-252-3557 |